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In recent years several studies have aimed at revealing the patho-
biochemical functions of cathepsin B (cath B) in tumours and have
led to the hypothesis that the enzyme is relevant for the progres-
sion of tumours, i.e. metastasis (reviewed by Berquin and Sloane,
1995; Elliot and Sloane, 1996; Lah and Kos, 1998; Yan et al,
1998). There are a number of evidences, supporting this hypoth-
esis: the levels of cath B in tumours were elevated above the levels
in adjacent normal tissue as demonstrated for example in lung
carcinoma (Trefz et al, 1989; Krepela et al, 1990; Sukoh et al,
1994a, 1994b; Ebert et al, 1994; Ledakis et al, 1996; Werle et al,
1997a, 1997b), breast carcinoma (Lah et al, 1992, 1995a), colon
carcinoma (Shuja et al, 1991), head and neck carcinoma (Budihna
et al, 1996), oesophageal carcinoma (Hughes et al, 1998) and
glioma (Rempel et al, 1994; Mikkelsen et al, 1995). Elevated
levels of the enzyme were also found in sera of tumour patients
(Leto et al, 1997; Kos et al, 1997, 1998). Cath B was found
concentrated at the invasive edges of colon carcinoma (Emmert-
Buck et al, 1994). In vitro, tumour cells were found to be able to
target cath B to the plasma membrane of tumour cells and to focal
adhesion points relevant for motility to a greater extent than in
normal cells (Rozhin et al, 1987; Sloane et al, 1987, 1994; Erdel et
al, 1990; Strohmaier et al, 1997). Increased secretion of the inac-
tive proform or the active enzyme (Werle et al, 1994, 1996) was
sensitive to external stimuli, i.e. changes in pH or signal mediator
12(S)-HETE (Rozhin et al, 1994; Honn et al, 1994; Ulbricht et al,
1996). The balance between the enzyme and its physiological
inhibitors seems to be disturbed in tumours (Knoch et al, 1994;
reviewed by Calkins and Sloane, 1995; Lah et al, 1997) and
finally, in vitro concerted inhibition of cath B and collagenases led
to the most effective reduction of extracellular matrix degradation
(Stonelake et al, 1997).
The problem in defining a role of cath B in tumour progression
arises from the fact that the enzyme is coded by a housekeeping
gene, present in all, tumour and normal cells. Moreover, cath B
was also found in tumour surrounding stromal cells and particu-
larly in activated monocytes, which produce increased levels of
cath B (Lah et al, 1995b). The interplay between tumour and
tumour surrounding cells, including autocrine and paracrine mech-
anisms, resulting in an overproduction of cath B by different cell
types, is still not well understood (Opdenakker et al, 1992).
However, the appearance of the enzyme in tumours, if associated
with malignancy and metastasis may be useful in prediction of
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Summary In order to evaluate the possible role of the proteolytic enzyme cathepsin B (cath B) in human non-small cell lung cancer (NSCLC) we
examined cath B concentrations (cath Bc) and activities (cath BA) in homogenates of 127 pairs of lung tumour tissues and corresponding non-
tumourous lung parenchyma. Total cath B activity (cath BAT) and enzymatic activity of the fraction of cath B, which is stable and active at pH 7.5
(cath BA7.5) were determined by a fluorogenic assay using synthetic substrate Z-Arg-Arg-AMC. The immunostaining pattern of cath B was
determined in 239 lung tumour tissue sections, showing the presence of the enzyme in tumour cells (cath BT-I) and in tumour-associated
histiocytes (cath BH-I). The median levels of cath BAT, cath BA7.5 and cath BC were 5.6-, 3.2- and 9.1-fold higher (P < 0.001), respectively, in tumour
tissue than in non-tumourous lung parenchyma. Out of 131 tissue sections from patients with squamous cell carcinoma (SCC), 59.5%
immunostained positively for cath B, while among the 108 adenocarcinoma (AC) patients 48.2% of tumours showed a positive reaction. There
was a strong relationship between the levels of cath BAT, cath BA7.5, cath BC and cath BT-I in the primary tumours and the presence of lymph node
metastases. Significant correlation with overall survival was observed for cath BT-I and cath BA7.5 (P < 0.01 and P < 0.05, respectively) in patients
suffering from SCC. In these patients positive cath B in tumour cells (cath BT-I) and negative cath B in histiocytes (cath BH-I) indicated significantly
shorter survival rate compared with patients with negative cath BT-I and positive cath BH-I (P < 0.0001). In contrast, in AC patients, both, positive
cath BT-I and positive cath BH-I, indicated poor survival probability (P < 0.014). From these results we conclude that the proteolytic enzyme cath B
is an independent prognostic factor for overall survival of patients suffering from SCC of the lung. © 1999 Cancer Research Campaign
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treatment and thereby improving the effectiveness of post-opera-
tive therapy.
Higashiyama et al (1991, 1993) demonstrated increased expres-
sion of cath B in lung adenocarcinomas. Sukoh et al (1994a,
1994b) performed retrospective immunohistochemical studies,
which showed that patients with tumours, strongly positive for
cath B, had a significantly shorter overall survival compared with
patients, which were negative for cath B. The authors recom-
mended cath B as an independent prognostic marker in non-small-
cell lung cancer (NSCLC), similar as concluded also by Inoue et al
(1994). We have also demonstrated a correlation between high
native cath B activity at pH 6.0 (cath BAT) and shorter survival
probability of lung cancer patients (Ebert et al, 1994). Recently,
even more significant correlation with shorter survival was found
for high activity of cath B-fraction, which was stable and active at
pH 7.5 (cath BA7.5) (Werle et al, 1997b). However, these studies
were performed on relatively small population of patients and by
a unifactorial methodological approach.
Here, we present an extended study on cath B activity and
protein concentration in comparison with immunohistochemical
(IHC) analysis of lung tumour sections of the same tumours. IHC
analysis would have an advantage over immunochemical and
activity analysis of tumour homogenates, due to the simplicity and
less tumour tissue needed and would also allow for the discrimina-
tion between tumour cell and histiocytes associated cath B. Taken
all results together, we demonstrated that IHC analysis of cath B
offers a simple and independent prognostic factor for overall
survival of patients with squamous cell carcinoma (SCC) of the
lung.
PATIENTS, MATERIALS AND METHODS
Patients
We investigated two groups of patients for the levels of cath B. In
the first group, comprising randomly selected 127 patients (15–81
years of age, mean 58.9 years, 104:23 male:female) we determined
enzymatic activities and protein concentration, using an enzyme-
linked immunosorbent assay (ELISA). Immunohistochemical
(IHC) analysis was performed in 92 out of these 127 patients and
in an additional 147 patients (38–87 years of age, mean 61.0 years,
114:33 male:female), comprising therefore a total of 239 samples
for IHC analysis. Cell typing of lung cancer was based on the
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Table 1 Cathepsin B in lung tumour homogenates
Cath BAT Cath BA7.5 Cath BC
(mEU mg–1 protein–1)( mEU mg–1 protein–1) (ng mg–1 protein–1)
Tumour Normal Tumour Normal Tumour Normal
n median median Tu/Lu n median median Tu/Lu n median median Tu/Lu
(5%, 95%) (5%, 95%) median (5%, 95%) (5%, 95%) median (5%, 95%) (5%, 95%) median
Primary tumours (total) vs 127 1237a 223 5.55 124 394a 125 3.15 127 1215a 133 9.14
normal lung tissue (total) (286, 2597) (51, 1081) (33, 592) (35, 592) (357, 2692) (40, 367)
– Squamous cell carcinoma (SCC) 68 1168a 235 4.97 65 330a 125 2.64 68 1213a 121 10.00
(234, 2724) (47, 1058) (17, 1856) (29, 577) (479, 2702) (29, 312)
– Adenocarcinoma (AC) 59 1282a 200 6.41 59 397a 205 1.94 59 1217a 135 9.00
(439, 2585) (57, 1142) (124, 1772) (37, 636) (270, 2682) (56, 376)
pT1 20 1184 20 308 20 1233
(248, 4772) (14, 1856) (300, 2424)
pT2 75 1278 75 414 75 1210
(321, 3100) (55, 1721) (383, 2702)
pT3 20 1168 20 396 20 1379
(219, 2547) (9, 1893) (644, 2283)
pT4 12 1094 12 323 12 1049
(560, 2388) (39, 1624) (593, 3585)
pN0 43 1598 43 292 43 1147
(321, 3807) (30, 1749) (298, 2283)
pN1 43 1124 43 414 43 1345
(218, 2149) (17, 1624) (574, 3125)
pN2 27 970 27 443 27 1054
(514, 2597) (117, 1893) (529, 2682)
pN3 14 1819 14 760 14 1764
(353, 2508) (190, 1772) (864, 3382)
pTNM I 35 1598 35 301 35 1147
(321, 6820) (30, 1856) (270, 2615)
pTNM II 24 1224 24 428 24 1388
(218, 2149) (17, 2248) (616, 2702)
pTNM IIIa 36 1008 36 352 36 1222
(271/2597) (27/1893) (556/2283)
pTNM IIIb 19 1145 19 733 19 2048
(353, 2388) (39, 1772) (593, 3585)
pTNM IV 13 1423 13 408 13 1177
(898/2573) (59/1238) (707/1636)
aCathepsin B values were significantly increased in tumour tissue (Tu) compared to its corresponding lung parenchyma (Lu), P < 0.001.predominant cell type and was done according to the WHO
protocol (World Health Organization, 1981). The tumour disease
stage (pTNM) was classified according to the international staging
system (Hermanek and Sobin, 1987). All patients included in this
study were subjected to surgery, also 51 patients with pTNM IIIb
and those 21 patients with pTNM IV, who undergo curative
surgery due to incorrect preoperative clinical staging (cTNM) or
due to individual favourable conditions. None of these patients
were exposed to radiation therapy and received chemotherapy
prior to surgery. After curative surgery patients in low stages were
kept under surveillance, while patients in high stages additionally
received adjuvant or palliative chemotherapy and/or radiation
therapy (Manegold and Drings, 1998; Schraube et al, 1998).
Cathepsin B activity (cath BAT, cath BA7.5) assays
Both assays were performed exactly as described in detail earlier
(Werle et al, 1997a, 1997b). Total cath BAT activity was measured
with the substrate Z-Arg-Arg-AMC at pH 6.0. To receive the cath
B fraction, which is stable and active at pH 7.5 (cath BA7.5), tissue
homogenates were preincubated for 60 min at pH 7.5 and residual
cath B activity was determined at the same pH. Specificity of the
cath B fraction, which is stable and active at pH 7.5 (cath BA7.5)
was verified by using the synthetic inhibitor CA-074.
Cathepsin B ELISA
Human cath B protein (cath BC) in lung tissue homogenates was
analysed using an ELISA (KRKA d.d., Novo mesto, Slovenia).
The components were purified and characterized and the test was
optimized as described (Kos et al, 1995, 1997). The antibodies
used for cath B ELISA recognize precursors, the mature form of
the enzyme as well as enzyme-inhibitor complexes (Kos et al,
1995). A microplate reader (SLT Rainbow, Austria) was used to
measure absorbance. Cath B determined in ng ml–1 was standard-
ized in ng mg–1 total protein of the tissue homogenates.
Determination of protein concentration
Protein concentration was determined according to Bradford
(1976). Bovine serum albumin was used as a standard.
Immunohistochemistry
Sections (3–5 mm) from formalin-fixed, paraffin-embedded
tumour tissues were used for immunohistochemistry (IHC) (Hsu
et al, 1981; Kayser and Gabius, 1997). Briefly, lung tumour tissue
sections were deparaffinized by xylene (2 ´ 5 min) and rehydrated
through alcohol 99% (2 ´ 5 min), 96% (1 ´ 2 min), 70%
(1  ´ 2 min), 50% (1 ´ 2 min) to phosphate-buffered saline (PBS),
pH 7.4 (3 ´ 3 min). After blocking: (i) endogenous peroxidase
with 2% methanolic hydrogen peroxide for 15 min, (ii) non-
specific binding sites with 5% normal goat serum in PBS for 30
min at room temperature, tissue sections were rinsed in PBS (3 ´ 3
min) and incubated with sheep IgG anti-cath B (KRKA) 1:200
diluted in PBS containing 5% normal goat serum in a humid
chamber at room temperature overnight. After washing in PBS
(3 ´ 3 min), tissue sections were incubated with biotinylated rabbit
anti-sheep antibody (Vector Laboratories, Serva Heidelberg,
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Table 2 Immunohistochemical analysis of cathepsin B in lung tumour tissue
Cath BT-I
b
(no vs yes)
Tumour
na No Yes
Primary tumours (total) 239 109 130
SCC 131 53 78
AC 108 56 52
pT1 35 20 15
pT2 144 67 77
pT3 33 12 21
pT4 23 7 16
pN0 95 45 50
pN1 71 33 38
pN2 50 21 29
pN3 19 7 12
pTNM I 80 40 40
pTNM II 41 16 25
pTNM IIIa 64 31 33
pTNM IIIb 32 9 23
pTNM IV 18 10 8
aAddition of subgroups is not equal to 239 and 147, because four TNMx
categories could not be assessed. b92 lung tumour tissue sections consisting
of 53 SCC and 39 AC out of 127 tissue samples were analysed in order to
perform correlations with cath B assays.
A
B
Figure 1 Immunohistochemical staining of cath B in tissue sections derived
from (A) a squamous cell carcinoma (SCC) and (B) an adenocarcinoma
(AC). Magnification ´ 256. Immunostaining was performed by using a
polyclonal antibody directed against cath B. The colour was developed with
3,3¢-diaminobenzidine and hydrogen peroxide. This SCC sample represents
the pattern observed in the majority of SCC sections with strongest
immunoreactivity of cath B at the periphery of tumour cell foci embedded in
the stroma (arrows). Cath B distribution in AC is a granular cytoplasmatic
staining (arrows). Histiocytes were identified at higher magnification and
marked by arrowheadsGermany) in PBS with 5% normal goat serum for 30 min and
with the Vectastain ABC Reagent (Vector) for 30 min. Peroxidase
activity was developed with 3,3¢-diaminobenzidine tetrahy-
drochloide (0.3 mg ml–1 in 0.05 M Tris-buffer, pH 7.5), including
0.2% hydrogen peroxide for 10–15 min. Finally, tissue sections
were light counterstained with 5% Harris’s haematoxylin, dehy-
drated and mounted.
For IHC, the following control assays were performed: (i) incu-
bation as in the assay, omitting the primary antibody; (ii) incuba-
tion omitting secondary antibody. Tissue sections were inspected
by two independent pathologists (EK and KK). Both pathologists
knew neither the diagnosis of the patients nor the result of the eval-
uation from each other. Both evaluations agree to 93%. Residual
7% were re-examined. The IHC scoring was performed separately
for cath B in tumour cells (cath BT-I) and cath B in histiocytes (cath
BH-I). Sections were classified into two groups according to the
number of positively stained tumour cells or histiocytes and were
considered positive for cath BT-I or cath BH-I when > 5% of stained
cells were present. The intensity of staining was not considered as
we observed that the intensity parallels the frequency (percentage)
of immunopositive cells, similar as already reported (Castiglioni et
al, 1994).
Statistical analyses
To compare data of pairs of tumour and lung tissue, we used the
two-tailed Wilcoxon’s rank test. Differences in cath B levels in
different groups of patients were tested by Mann–Whitney and
Kruskal–Wallis test. The correlation between activities (cath BAT,
cath BA7.5) and concentration (cath BC) was calculated by non-
parametric regression analysis and the significance of the
Spearman rank correlation coefficient was evaluated by analysis of
variance (ANOVA). Homogeneous variables, cath BAT, cath BA7.5,
cath BC, were recoded into two new groups based on the immuno-
histochemical evaluation cath BT-I: negative and positive respec-
tively. For correlation between these two new groups of cath BAT,
cath BA7.5, cath BC and between the IHC scoring with different
pTNM categories, Pearson’s c2 and Fisher’s exact test were used.
Univariate analysis of survival probability was performed by
Kaplan and Meier analysis (1958), using the log-rank test for
determination of statistical significance between the survival
curves and multivariate analysis was performed using the Cox
proportional hazard model (Cox, 1972). The discrimination levels
of differentiate between subgroups of patients were calculated by
the Critlevel programme (Abel et al, 1984). Various statistical
packages (PC-Statistik, TOPSOFT, Hannover, Germany;
Statistica, StatSoft, Hamburg, Germany) were applied.
RESULTS
Distribution of cathepsin B in lung tumours
We measured enzymatic activities of total cath B at pH 6.0 (cath
BAT) and stable, active fraction at pH 7.5 (cath BA7.5) as well as
the concentration of the enzyme (cath Bc) in tissue extracts of
127 samples of NSCLC tumours and the corresponding non-
tumourous lung parenchyma. A summary of the data is given in
Table 1. The median levels of the enzymatic activities of cath BAT,
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Table 3 Correlations
Cath BAT Cath BA7.5 Cath BC Cath BT-I
Tumour/Lung Tumour/Lung Tumour/Lung Tumour/Lung
SCC n = 65
Cath BAT –– – –
Cath BA7.5 r 0.64/0.75 – – –
p < 0.001/< 0.001 – – –
Cath BC r 0.25/0.61 0.24/0.61 – –
P < 0.05/< 0.001 < 0.1/< 0.001 – –
Cath BT-I
a P 0.9/– 0.9/– 0.46/– –
AC n = 59
Cath BAT –– – –
Cath BA7.5 r 0.39/0.78 – – –
P < 0.01/< 0.001 – – –
Cath BC r 0.55/0.78 0.67/0.79 – –
P < 0.001/< 0.001 < 0.001/< 0.001 – –
Cath BT-I
a P < 0.05/– < 0.01/– < 0.1/– –
aHomogeneous variables, cath BAT, cath BA7.5, cath BC were recorded into two groups based on the immunohistochemical evaluation (cath BT-I) negative and
positive, respectively. To identify a relationship between the two new groups of cath BAT, cath BA7.5, cath BC we used Pearson’s c2 and Fisher’s exact test.
Table 4 Univariate survival analyses
Variable Histology Unfavourable vs P-value
favourable characteristics
pTNM-staging NSCLC TNM III b, IV vs TNM I, II, III a < 0.0001
Cath BT-I NSCLC (+) vs (–) < 0.0001
Cath BT-I SCC (+) vs (–) 0.00017
Cath BH-I SCC (+) vs (–) 0.028
Cath BT-I AC (+) vs (–) 0.039
Cath BH-I AC (+) vs (–) 0.05
Cath BA7.5 SCC > 292 vs < 292 (mEU mg–1)a 0.037
Cath BA7.5 AC > 292 vs < 292 (mEU mg–1)a 0.98
Cath BAT SCC > 1674 vs < 1674 (mEU mg–1)a 0.19
Cath BAT AC > 1674 vs < 1674 (mEU mg–1)a 0.91
Cath BC SCC > 512 vs < 512 (ng mg–1)a 0.31
Cath BC AC > 512 vs < 512 (ng mg–1)a 0.93
Age SCC > 60 years vs < 60 years 0.6
Sex SCC Male vs Female 0.23
aCut-off values were calculated by a computer program developed by Abel et
al (1984).514 B Werle et al
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cath BA7.5 and the cath Bc are 5.6-, 3.2- and 9.1-fold higher in
tumour than in non-tumour lung parenchyma. The significance
(P < 0.001) between tumour and normal tissue is high, although
we observed certain overlapping in the activities and the concen-
tration levels between tumour and non-tumour tissues. By taking
the 99% percentile of the normal level of cath BAT (1278 [mEU
mg–1 protein–1]), cath BA7.5 (923 [mEU mg–1 protein–1]) and cath BC
(512 [ng mg–1 protein–1]), considered as the upper limit of
‘normal’, we found an overlap with 52%, 80%, but only 7% of the
respective tumour cases. Therefore, best discrimination between
tumour and control tissue is indicated by increased cath B concen-
trations with a sensitivity of 93% and with a specificity of 99%.
For an IHC analysis (Table 2) we combined 92 out of the 127
samples where the cath B assays were performed with a second
independent group of 147 samples, comprising the total of 239
NSCLC samples. According to histology, 131 of these patients
suffered from squamous cell carcinoma (SCC) and 108 patients
from adenocarcinoma (AC). Immunostaining for cath B was posi-
tive in 130 out of 239 of tissue sections (54.4%).
All these data were analysed with respect to tumour histology
and pTNM-staging (as shown on Tables 1 and 2). There was no
significant difference in the median levels of both types of cath B
activities and cath BC between SCC and AC. We did not find a
correlation with tumour size (pT) while cath BAT, cath BA7.5 and
cath BC in primary tumours correlated very strongly with lymph
node metastasis (pN status). These three parameters were signifi-
cantly higher (P < 0.01, P < 0.05 and P < 0.01 respectively) in
primary tumours of patients with lymph node metastases stage
pN3 compared to the primary tumours without lymph node metas-
tases (pN0). A steady increase of the median level of cath BA7.5
activity was also observed from pN0 over pN1, pN2 to pN3
tumours, which was close to significance (P = 0.073). Significant
association between cath BC and pTNM stages was observed, as
the median value of cath BC was significantly (P < 0.01) higher in
pTNM IIIb than pTNM I tumours, although not in pTNM IV
tumours.
Table 2 shows that a clear positive immunoperoxidase reaction,
associated with tumour cells, was observed among 131 SCC
sections (59.5%) and 48.2% out of the 108 AC sections. However,
there were significant differences in the staining patterns. In AC
samples, the staining was distributed over the cytoplasm (Figure
1B) while in SCC samples, the intensity of immunoreactive cath B
was strongest at the periphery of tumour cell foci embedded in
non-tumour cell material (Figure 1A). Inflammatory cells such as
histiocytes were always found associated with lung tumour cells
and stained positively for cath B (cath BH-I) in 102 out of 131
sections (77.9%) of SCC samples and in 75 out of 108 AC sections
(69.5%). Cath BT-I was found to be more frequently positive in
pT4- than in pT1-tumours and was more frequently positive in
SpN1/pN2/pN3 than in pN0 tumours. Similar as for the total cath
B concentration, positive labelling of tumour cell associated cath
B (cath BT-I) was observed in higher pTNM stages, as pTNM IIIb
tumours were more frequently labelled than the pTNM I tumours
(P < 0.05).
Correlation
The correlation’s between evaluated cath B parameters are listed in
Table 3. In contrast to SCC we found in AC a positive correlation
between all levels of cath B expression, cath B activities (cath BAT,
cath BA7.5), cath B concentration and cath BT-I (P < 0.05, P < 0.01,
and  P < 0.1, respectively). In addition, the correlation in AC
between cath BAT, cath BA7.5 and cath B concentration (both P <
0.001) was stronger compared to SCC (P < 0.05 and P < 0.1,
respectively). In lung parenchyma of patients with SCC as well as
with AC there was a significant correlation between cath B
activities and cath B concentration (in all cases P < 0.001 and
P < 0.001).
Association of cath B activities, concentrations and
immunostaining with survival probability
For prognosis of patients with NSCLC the histological cell type
and the stage of the disease are the most important prognostic
factors used in the clinical routine. In order to evaluate prognostic
value of cath B alone and in comparison with the established clin-
ical prognostic factors, we performed univariate and multivariate
survival analyses, respectively.
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Figure 2 Prognostic significance of tumour-associated cath B staining (cath
BT-I) for overall survival of patients. (A) Diagnosed for NSCLC, (B) diagnosed
for SCC and (C) diagnosed for AC. Immunoreactivity of cath B was evaluated
by two pathologists and scored as negative (< 5% positive tumour cells) and
positive (> 5% positive tumour cells). In NSCLC 79 out of 130 (A+), in SCC
48 out of 78 (B+), and in AC 31 out of 52 (C+) patients with positive in cath
BT-I had a significantly shorter overall survival (—n— deceased patients
(uncensored data), —x— still living patients (censored data)) than 37 out of
109 NSCLC- (A–), 16 out of 53 SCC- (B–) and 21 out of 56 AC- (C–) patients
with negative cath BT-I (–l– deceased patients, –x– still living patients)Univariate analyses
Table 4 presents the significance of prognosis for cath B variables
in comparison to the age and sex of the patients and for two
different histologies of lung tumours. In tumour homogenates cath
BAT and cath BC showed no significant prognostic value for 5-year
survival (Table 4). Noteworthy, for total population of NSCLC
patients and for SCC patients cath BAT and cath BA7.5 were of prog-
nostic significance in short observation periods of 6 months
(NSCLC: cath BAT, P < 0.05) or 15 months (NSCLC and SCC: P <
0.05 and P < 0.05 respectively, data not shown). However, IHC
analysis revealed that tumour cell associated cath B (cath BT-I) was
of prognostic significance for 5-year survival in the total popula-
tion of NSCLC cancer patients (n = 239, P < 0.0001). Comparing
the two different histologies cath BA7.5 and cath BT-I were also of
prognostic significance for SCC patients (n = 65, P < 0.05; n =
131, P < 0.001, respectively), as illustrated in Figure 2. In AC
Cathepsin B in lung tumours 515
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Table 5 Cox regression analyses
Variable Unfavourable vs Relative P-value
favourable characteristics risk
Multivariate I (NSCLC)
pTNM-staging TNM III b, IV vs TNM I, II, IIIa 2.88 (2.4–3.5) < 0.00001
Cath BT-I (+) vs (–) 1.88 (1.5–2.3) 0.0018
Multivariate II (SCC)
pTNM-staging TNM III b, IV vs TNM I, II, IIIa 3.33 (2.5–4.4) < 0.000021
Cath BT-I (+) vs (–) 2.43 (1.8–3.3) 0.0028
Multivariate III (SCC)
pTNM-staging TNM III b, IV vs TNM I, II, IIIa 2.71 (1.8–4.1) 0.012
Cath BA7.5 > 292 vs < 292 (mEU mg–1) 2.31 (1.6–3.4) 0.032
Multivariate IV (AC)
pTNM-staging TNM III b, IV vs TNM I, II, IIIa 2.54 (1.9–3.4) 0.0014
Cath BT-I (+) vs (–) 1.56 (1.2–2.1) 0.12
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Figure 3 Prognostic significance of immunohistochemical analysis of cath B in tumour cells (cath BT-I) and in histiocytes (cath BH-I) for overall survival.
(A) SCC-patients with negative cath BH-I (–l–, –) have a significantly shorter overall survival than SCC patients with positive cath BH-I (—n—, +). (B) AC
patients with positive cath BH-I had the opposite impact on survival. (C) Combination of cath BT-I and cath BH-I for SCC-patients. Nine out of 11 patients with
positive cath BT-I but negative cath BH-I died in a 5-year observation period (–l–) but only seven out of 37 patients with negative cath BT-I and positive cath BH-I –
expression died (—n—), the difference being highly significant (P < 0.0001). Patients with either positive/positive or negative/negative reaction in both cell
types, were grouped together and show an intermediate survival rate (•••s•••). (D) Combination of cath BT-I and cath BH-I for AC patients. Seven out of 26
patients with negative cath BT-I and negative cath BH-I died in a 5-year observation period (–l–) and 30 out of 51 patients with positive cath BT-I and positive or
negative cath BH-I – expression died (—n—), the difference being highly significant (P = 0.014). The group with negative cath BT-I but positive cath BH-I (15/31)
had an intermediate survival probability (•••s•••). Comparison of all three groups by log-rank-test revealed a significance of P = 0.034516 B Werle et al
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patients (n = 108, P < 0.05), only cath BT-I was significant. The
IHC analysis also revealed that cath B in tumour associated histio-
cytes (cath BH-I) in SCC and AC had different prognostic impact
for survival (Figure 3 A,B). SCC patients with negative cath BH-I
had significantly shorter overall survival than SCC patients with
positive cath BH-I (P = 0.028), while AC patients with positive cath
BH-I had shorter survival rate (P < 0.05).
Furthermore, the combination of positive cath B in tumours and
cath B in tumour associated histiocytes was also of prognostic rele-
vance discriminating between additional subgroups of patients
(Figure 3 C,D). Nine out of 11 SCC patients with positive cath BT-I
but negative cath BH-I died within 5 years (median survival time 13.3
months). In contrast, in the group of patients with negative cath BT-I
and positive cath BH-I only 7 out of 37 patients died in this period.
The median survival time in this group was 35 months (P < 0.0001).
Patients with either positive cath BT-I and positive cath BH-I or nega-
tive cath BT-I and negative cath BH-I showed an intermediate value
and were therefore grouped together (the median survival time was
20.7 months). In contrast to this, in AC patients, the best survival
was observed in the group with negative cath BT-I and negative cath
BH-I: 7 out of 26 patients died in 5 years; the median/mean survival
time was 21.5/26.2 months respectively. The patients with positive
cath BT-I and positive or negative cath BH-I were grouped together: 30
out of 51 patients died in 5 years, the median/mean survival time
was 22.5/21.9 months respectively. The group with negative cath
BT-I and positive cath BH-I showed a median/mean survival time
of 24.5/21.9 months respectively. The probability of survival
between these groups differed significantly (P = 0.034).
Multivariate analyses
In the multivariate analysis, only factors with a significant rela-
tionship to the survival probability found by the univariate analysis
and independent from other factors were included. Thus, only two
factors were considered: pTNM-staging and either cath BT-I as
shown on Table 5 (Multivariate I, II, IV) or cath BA7.5 (Table 5,
Multivariate III). In the total population of NSCLC patients and in
patients with SCC, only pTNM staging and cath BT-I or cath BA7.5
were significant for prognosis. Cath B had no impact on prognosis
in patients with AC.
As demonstrated in Table 5, pTNM-staging remained the best
independent prognostic factor for patients with SCC and with AC.
In addition, in SCC patients only, cath BT-I and cath BA7.5 were
powerful independent prognostic factors.
To answer the question whether a combination of independent
prognostic factors cath BT-I, cath BA7.5 and the pTNM-staging
provide new information, patients were subdivided into two
groups consisting of patients in a low pTNM-stage (pTNM I–IIIa)
and a high pTNM-stage (pTNM IIIb and IV). Kaplan–Meier
analyses showed that only 23 out of 86 patients (Figure 4A) in
pTNM I–IIIa and negative cath BT-I compared to 46 out of 99
patients with pTNM I–IIIa and positive cath BT-I died within 5
years. The median survival time were 29.1 and 24.0 months.
Comparable results were obtained in patients with SCC, since only
seven out of 27 patients with low cath BA7.5 activities (values
< 292 [mEU mg–1]) in pTNM I–IIIa compared to 11 out of
25 patients with cath BA7.5 activity values above this cut-off point
in pTNM I–IIIa died within 5 years. The median survival times
were 36.8 and 12.0 months. For NSCLC-patients in high stage
pTNM IIIb and IV, cath BT-I did not further discriminate between
good and poor survival and both groups have the worst survival
probability. This is in contrast to patients with SCC, where patients
in pTNM-stage IIIb and IV and cath BA7.5 values below 292 [mEU
mg–1] have a better overall survival probability compared to those
patients above this cut-off point.
DISCUSSION
Previous studies on cath B in lung tumours, using either
homogenates (Krepela et al, 1990; Sedo et al, 1991; Ebert et al,
1994; Ledakis et al, 1996; Werle et al, 1997a, 1997b) or IHC
analysis of cath B (Higashiyama et al, 1991, 1993; Ozeki et al,
1993; Inoue et al, 1994; Sukoh et al, 1994a, 1994b), showed
significantly enhanced expression of the enzyme at activity and
protein levels in patients suffering from NSCLC. In this study, we
clearly confirmed our earlier results as we found 9.1-fold
increased cath B protein concentration as well as 5.6-fold
increased total cath B activity and 3.2-fold increase in the fraction
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Figure 4 Survival analyses of patients stratified by pTNM stage and by cath
BT-I and cath BA7.5: (A) pTNM-stage and cath BT-I for the total of 235 NSCLC
patients. (B) pTNM stage and cath BA7.5 for 131 SCC patients. In NSCLC-
and SCC patients the combination of pTNMI–IIIa and negative cath BT-I
(23/86) or low (< 292 mEU mg–1) cath BA7.5 (7/27)(–l–) is significantly
different from pTNM I–IIIa and positive cath BT-I (46/99) or high
(> 292 mEU mg–1) cath BA7.5 (11/25) (•••l l•••). No significant difference was
observed between NSCLC-patients with pTNM stage IIIb and IV and
negative cath BT-I (—s—), 26/31) compared with positive cath BT-I
(–n–, 14/19). A significant difference could be observed between SCC
patients with high pTNM stage IIIb, IV and low cath BA7.5 (–s–, 5/7)
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of cath B activity, stable at pH 7.5 (Werle et al, 1997b) in tumour
compared with normal lung tissue homogenates. Our data
concerning enzyme expression revealed by IHC agree with
previous investigations (Higashiyama et al, 1991, 1993; Ozeki et
al, 1993; Inoue et al, 1994; Sukoh et al, 1994a, 1994b) demon-
strating that more elevated levels of cath B were found in primary
tumours, which invaded into lymph nodes. Noteworthy, fraction of
cath B activity stable at pH 7.5 (cath BA7.5) steadily increased in
more malignant lung tumours (from pN1 to pN3). These data
strongly support the association of cath B with the pathobiochem-
ical mechanism of tumour progression.
In relation to prognosis, the histological type and the tumour
stage (TNM) of the lung tumours are considered as key factors
relevant to prognosis for patients with NSCLC. However, new
prognostic factors may still be needed to discriminate the patients
with worse prognosis in low risk, e.g. low TNM-stage tumours. In
this study, we found that tumour stage is still the best prognostic
factor, but in addition, we demonstrated that immunohistochem-
ical analysis of cath B, in particular tumour cell-associated cath B
(cath BT-I) is also a powerful independent prognostic factor in
NSCLC patients. In contrast, cath B activities (cath BAT, cath BA7.5)
and concentration (cath BC), measured in tumour homogenates,
had no prognostic relevance in the total population of NSCLC
patients in a 5-year observation period. This is in contrast to the
study by Ebert et al (1994) and Knoch et al (1994), but similar to
the recent study (Werle et al, 1997a). The discrepancy with earlier
studies is most likely due to longer observation period of 5 years in
the present study. It is interesting to note that cath BAT and cath
BA7.5 were of prognostic significance in shorter observation period
of 6 months (cath BAT, P < 0.05; Ebert et al, 1994) and 15 months
(both P < 0.05; unpublished data). When different histologies were
considered separately, prognostic relevance of cath BAT and cath
BA7.5 were found for patients suffering from SCC, already in
shorter observation period (Werle et al, 1997a). In contrast, in AC
no prognostic impact of cath BAT, cath BA7.5 and cath BC was found
in short (6, 15 and 24 months) and long (5 years) observation
period.
Our findings agree with other univariate- and the multivariate
survival analyses of cath B IHC analysis in tumour cells of adeno-
carcinoma (Sukoh et al, 1994a, 1994b). Moreover, Ozeki et al
(1993) further differentiated AC patients and demonstrated prog-
nostic significance of cath B for lung AC of the Clara cell type
only, but not for other subtypes of AC patients. The differences in
these results may be due to different reagents and protocols used
for IHC analysis and non-standardized scope of histological classi-
fications of AC subtypes. It is known from large scale studies, that
after surgery, the patients with SCC have a better overall survival
probability than those with AC (Mountain, 1991). As indicated
above, lung tumours of different histologies also differ with
respect to cath B expression, distribution and relevance to prog-
nosis. For example, in tumour homogenates, a fraction of cath B,
stable at pH 7.5, cath BA7.5 was a prognostic factor for SCC
patients, but not for AC patients (Werle et al, 1997a). There was a
significant correlation between cath BAT, cath BC and cath BT-I in
AC, which was not found in SCC tumours. Immunohistochemical
analysis of tumour cell associated cath B also revealed that the
distribution of cath B over the cytoplasm of the tumour cell in AC
was homogenous, while in SCC cath B was highly concentrated at
the periphery of tumour cell foci, indicating that this fraction of
cath B was possibly involved in tumour cell invasion. In these
tumours (AC), a significant difference for patients with positive
and negative expression of cath B in tumour cells (cath BT-I) was
found by the univariate analysis, but not in multivariate survival
analyses using Cox regression model. Although our results are in
close agreement to large-scale studies of Sukoh et al (1994a,
1994b) and Ozeki et al (1993), there still exists a recent report
from Mori et al (1997), who could not demonstrate a significant
correlation between cath B overexpression and overall survival
probability of 31 lung cancer patients in TNM stage I. The discrep-
ancy between these studies might be due to an insufficient number
of patients in the study of Mori et al (1997), distinct staining
procedures, which included the use of divergent cath B antisera
and different cut-off values for gradation of cath B stained tissue
sections. However, cath B was also positive in 11 out of 12 SCC
and 11 out of 15 AC tumours demonstrating an overexpression of
cath B in lung tumours.
Immunohistochemistry also allows for a distinction between
different cell types in tumour sections and we demonstrated a
strong positive staining also in tumour-associated histiocytes, cath
BH-I. In SCC patients, the presence of cath B in histiocytes had an
impact on longer survival and this effect was stronger in cath BT-I-
negative tumours. AC positive cath BH-I indicated worse prog-
nosis, particularly in tumours with positive cath BT-I in tumour
cells. These results indicate a possible role of cath B in tumour
associated histiocytes. In general, the role of macrophages is still
controversial. On one hand, activated macrophages are cytotoxic
to tumour cells, as for example, interferon-gamma cured murine
tumours in metastasis (Fidler, 1974), although the regression of
primary tumours was not observed. Similarly, in-situ activated
macrophages are involved in host resistance to lymphoma metas-
tasis probably by a production of nitric oxide (Umansky et al,
1995). On the other hand, macrophages were found to directly
stimulate tumour cell growth, inducing neovascularization and
tissue dissolution. Furthermore somatic hybridization of tumour
cells with the inflammatory macrophages was observed, resulting
in highly metastatic variants of the original clones (Mantovani,
1990). We therefore suggest that different pathobiochemical
mechanisms, involving cath B of macrophages, might be respon-
sible for malignant progression of lung tumours of different
histologies.
In conclusion, out of all cath B variables, only positive cath BT-I
in NSCLC/SCC patients and high cath BA7.5 in SCC patients
had high impact on prognosis in a 5-year observation period.
Furthermore, in low pTNM stages (I, II and IIIa) overexpression
of cath BT-I in NSCLC patients and high cath BA7.5 in SCC patients,
indicated worse prognosis. Overexpression of cath BH-I in histio-
cytes might be useful in discriminating patients with higher risk
for survival, depending on tumour histology.
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